Literature DB >> 22918165

BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.

Renu K Virk1, Alison L Van Dyke, Alexander Finkelstein, Avinash Prasad, Joanna Gibson, Pei Hui, Constantine G Theoharis, Tobias Carling, Sanziana A Roman, Julie A Sosa, Robert Udelsman, Manju L Prasad.   

Abstract

BRAF(V600E) mutation has emerged as a marker of aggressive behavior in papillary thyroid carcinoma but its significance in microcarcinoma is not entirely clear. One-hundred and twenty-nine papillary thyroid microcarcinomas were tested for BRAF(V600E) mutation by single-strand conformation polymorphism, and their clinicopathologic features (age, sex, tumor size, multifocality, nodal metastases, histologic subtype, tumor cell morphology, architecture, tumor-associated stromal reaction, tumor interface to non-neoplastic thyroid (well circumscribed vs infiltrative), extrathyroidal extension, lymphovascular invasion, intratumoral multinucleated giant cells, and adjacent non-neoplastic thyroid pathology) were examined. Compared with tumors without the mutation (39/129, 30%), the mutated microcarcinomas (90/129, 70%) showed significantly higher prevalence of infiltrative tumor borders (78/90 vs 23/39, P=0.001), tumor-associated stromal desmoplasia/fibrosis and/or sclerosis (80/90 vs 25/39, P=0.002), classic nuclear features of papillary thyroid carcinoma (90/90 vs 35/39, P=0.008) and cystic change (43/90 vs 11/39, P=0.05). BRAF(V600E) mutation was more frequent in classic (75%), tall cell (91%), and other variants (>70%) than in follicular variant (21%) of papillary thyroid microcarcinoma. Tumors without the mutation were significantly more likely to be solid, well circumscribed, and lacked desmoplasia/fibrosis or sclerosis. However, on multivariate analysis, only the follicular variant of papillary microcarcinoma was significantly associated with the absence of mutation (odds ratio (95% confidence interval): 0.09 (0.01-0.54)). Lymph node metastases (n=24) were more frequent in microcarcinomas with mutation than without (21/24 vs 3/24, P=0.02). All patients with lateral cervical node metastasis (n=9), and all but one tumor with extrathyroidal extension (n=17/18) showed BRAF(V600E) mutation. No significant differences were noted in age, sex, tumor size, multifocality, lymphovascular invasion, psammoma bodies, stromal calcification, intratumoral multinucleated osteoclastic-type giant cells, and lymphocytic infiltration between the two groups of tumors. BRAF(V600E) mutation is an early event in thyroid carcinogenesis, and is associated with distinctive morphology and aggressive features even in papillary thyroid microcarcinomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918165     DOI: 10.1038/modpathol.2012.152

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  29 in total

1.  BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.

Authors:  Giovanni Tallini; Dario de Biase; Cosimo Durante; Giorgia Acquaviva; Michele Bisceglia; Rocco Bruno; Maria Letizia Bacchi Reggiani; Gian Piero Casadei; Giuseppe Costante; Nadia Cremonini; Livia Lamartina; Domenico Meringolo; Francesco Nardi; Annalisa Pession; Kerry J Rhoden; Giuseppe Ronga; Massimo Torlontano; Antonella Verrienti; Michela Visani; Sebastiano Filetti
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

2.  Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer.

Authors:  Jae Won Chang; Ki Wan Park; Jae Hyung Heo; Seung-Nam Jung; Lihua Liu; Sung Min Kim; In Sun Kwon; Bon Seok Koo
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

3.  Therapeutic Strategies and Clinical Outcome in Papillary Thyroid Microcarcinoma: A Multicenter Observational Study.

Authors:  F Cecoli; E M Ceresola; V Altrinetti; M Cabria; M Cappagli; A Montepagani; C M Cuttica; U Filippi; D Saverino; M Raffa; M Caputo; F Minuto; M Giusti; M Bagnasco
Journal:  Eur Thyroid J       Date:  2016-06-02

Review 4.  The association between BRAF (V600E) mutation and pathological features in PTC.

Authors:  Xin Liu; Kangkang Yan; Xuejun Lin; Longyu Zhao; Wenxiu An; Chunpeng Wang; Xiaodong Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-04       Impact factor: 2.503

5.  Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.

Authors:  Maria Teresa Samà; Enrico Grosso; Chiara Mele; Sara Laurora; Oriana Monzeglio; Paolo Marzullo; Renzo Boldorini; Paolo Aluffi Valletti; Gianluca Aimaretti; Maria Scatolini; Loredana Pagano
Journal:  Endocrine       Date:  2020-07-03       Impact factor: 3.633

6.  Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules.

Authors:  Lingying Yu; Lizhen Ma; Qiaofeng Tu; Y I Zhang; Yueming Chen; Daojun Yu; Shaoyu Yang
Journal:  Oncol Lett       Date:  2015-04-15       Impact factor: 2.967

Review 7.  The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Authors:  Roberto Vita; Antonio Ieni; Giovanni Tuccari; Salvatore Benvenga
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

8.  Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study.

Authors:  Renu K Virk; Constantine G A Theoharis; Avinash Prasad; David Chhieng; Manju L Prasad
Journal:  Virchows Arch       Date:  2014-02-19       Impact factor: 4.064

9.  BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.

Authors:  Yu-Jia Ma; Xiu-Ling Deng; Hui-Qing Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

10.  Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis.

Authors:  Eric J Kuo; Paolo Goffredo; Julie A Sosa; Sanziana A Roman
Journal:  Thyroid       Date:  2013-09-14       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.